Navigation Links
Compound Tied to Cognitive Deficits in Schizophrenia
Date:11/19/2008

High kynurenic acid levels like 'gasoline on the fire' of affected neurotransmitters

WEDNESDAY, Nov. 19 (HealthDay News) -- Elevated brain levels of a compound called kynurenic acid are associated with problem-solving deficits in people with schizophrenia, according to U.S. researchers.

Drugs that suppress kynurenic acid might be used in conjunction with antipsychotic drugs to treat cognitive impairments, the most resistant symptoms in schizophrenia patients, the researchers said.

"We've got this core cluster of symptoms that is the Achilles' heel for these individuals, and we're not really doing a good job of treating them," principal investigator John P. Bruno, professor of psychology, psychiatry and neuroscience at Ohio State University, explained in a university news release.

Kynurenic acid is present in all human brains and has useful functions. However, an excessive amount of the compound interferes with other chemical processes involved in the ability to pay attention and think strategically under changing circumstances, said Bruno and colleagues, who conducted their research in rats.

A group of rats was given a compound that stimulated excess production of kynurenic acid and compared to a control group of normal rats. Both groups were tested on their ability to make decisions when subjected to changing conditions. Only 28 percent of the rats with elevated kynurenic acid were able to solve problems to receive a food reward, compared with 100 percent of the normal rats.

Increased levels of kynurenic acid exacerbate an existing problem in people with schizophrenia, who have lower-than-normal levels and activity of two neurotransmitters (acetylcholine and glutamate) critical to normal cognition, the researcher said. The activity of these neurotransmitters is partially regulated by a class of proteins called alpha-7 receptors. Excess levels of kynurenic acid inhibit the action of alpha-7 receptors.

"So, we've already got problems with these neurotransmitters, and then to make matters worse, we've got all this extra kynurenic acid antagonizing the alpha-7 receptors, which just throws gasoline on the fire," Bruno said. "If we can design drugs that are able to inhibit the enzymes that are responsible for overproducing kynurenic acid, we may improve cognitive performance in these patients."

The research was to be presented Nov. 18 at the Society for Neuroscience meeting in Washington, D.C.

More information

Mental Health America has more about schizophrenia.



-- Robert Preidt



SOURCE: Ohio State University, news release, Nov. 18, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Coloring Compound in Fruits, Veggies May Cut Colon Cancer Risk
2. Sugary Sodas High in Diabetes-Linked Compound
3. Red wine compound shown to prevent prostate cancer
4. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
5. A Chinese medicine compound has satisfactory anti-cancer effects on hepatocellular carcinoma
6. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
7. Organon Signs an Exclusive, Worldwide Licence Agreement on Advanced Antithrombotic Compounds With Endotis Pharma
8. Primus Innovations and Health Robotics Launch Strategic Partnership to Accelerate Transformation in Chemotherapy Compounding
9. Cannabis Compound May Stop Metastatic Breast Cancer
10. Prostate Cancer Treatments Often Compound Existing Health Problems
11. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Compound Tied to Cognitive Deficits in Schizophrenia
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch ... Inc. (NCADD) is recommending the film Whispering Spirits and its discussion ... of Columbia as an education tool in the war against teen drug abuse. ...
(Date:12/9/2016)... NJ (PRWEB) , ... December 09, 2016 , ... ... Founders Ball at The Pierre Hotel in New York, NY, on December 3rd, ... benefactors, dignitaries and physicians attended the annual event, which raised over $1 million ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
(Date:12/8/2016)... ... 08, 2016 , ... ZyDoc , a New York-based ... Data Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” ... comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand ... “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety ... dental implant and prosthetic market in the U.S. is projected to reach $6.4 billion ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX ... Nationwide Children,s Hospital signed a membership ... accelerate the development of new cures. ... representing over 57 million patients globally, biopharmaceutical companies ... together to improve protocol design, site selection, patient ...
(Date:12/8/2016)... HARRISBURG, Pa. , Dec. 8, 2016 /PRNewswire-USNewswire/ ... and Secretary of Drug and Alcohol Programs ... anxiety and insomnia medications, known as benzodiazepines, developed ... "Benzodiazepines are medications that are frequently ... "However, when they are used with opioid pain ...
(Date:12/8/2016)... 2016  A new study by a pair of ... opioid therapy to treat chronic pain is not only ... harmful consequences, including death. Palliative care physicians ... Mehta , M.D., authored the study which provides a ... The study was published in the December 2016 edition ...
Breaking Medicine Technology: